Literature DB >> 18245147

Markers of treatment failure in hospitalised community acquired pneumonia.

R Menéndez1, M Cavalcanti, S Reyes, J Mensa, R Martinez, M A Marcos, X Filella, M Niederman, A Torres.   

Abstract

BACKGROUND: Lack of response to treatment in community acquired pneumonia (CAP) worsens outcome. We evaluated the systemic cytokine profile (tumour necrosis factor alpha, interleukin (IL)1, IL6, IL8 and IL10), C reactive protein (CRP) and procalcitonin (PCT) in patients with CAP who had treatment failure.
METHODS: A prospective study was performed in hospitalised patients with CAP. Cytokines, PCT and CRP measurements were obtained on day 1 and after 72 h of treatment. Treatment failure was the endpoint evaluated, with separation of those with early (< or = 72 h) or late failure.
RESULTS: 453 patients were included: 84 (18%) had treatment failure, of whom 38 (8%) were early failures. Median levels of IL6, PCT and CRP on days 1 and 3 and median levels of IL8 on day 1 were significantly higher in patients with any treatment failure. Logistic regression analysis demonstrated that values above the cut-off points for IL6 (> or = 169 pg/ml), IL8 (> or = 14 pg/ml) and CRP (> or = 21.9 mg/dl) on day 1 had independent predictive value for any treatment failure after adjustment for initial severity; relative risks (OR) found were 1.9, 2.2 and 2.6, respectively. Increased levels for CRP and PCT on day 1 were also independent predictors for early failure. Increased levels for IL6 and CRP were the best predictors of late failure.
CONCLUSIONS: Serum levels of CRP, IL6 and PCT on days 1 and 3 were independently associated with a higher risk of any treatment failure. Low levels of PCT and CRP on day 1 had a high negative predictive value for early failure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245147     DOI: 10.1136/thx.2007.086785

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  34 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 2.  Statins for community-acquired pneumonia: current state of the science.

Authors:  D Viasus; C Garcia-Vidal; F Gudiol; J Carratalà
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-11-27       Impact factor: 3.267

Review 3.  Community-acquired pneumonia: identification and evaluation of nonresponders.

Authors:  João Gonçalves-Pereira; Catarina Conceição; Pedro Póvoa
Journal:  Ther Adv Infect Dis       Date:  2013-02

4.  Statin Use and Hospital Length of Stay Among Adults Hospitalized With Community-acquired Pneumonia.

Authors:  Fiona Havers; Anna M Bramley; Lyn Finelli; Carrie Reed; Wesley H Self; Christopher Trabue; Sherene Fakhran; Robert Balk; D Mark Courtney; Timothy D Girard; Evan J Anderson; Carlos G Grijalva; Kathryn M Edwards; Richard G Wunderink; Seema Jain
Journal:  Clin Infect Dis       Date:  2016-05-10       Impact factor: 9.079

5.  When antibiotic treatment fails.

Authors:  Matteo Bassetti; Josè Garnacho Montero; José Artur Paiva
Journal:  Intensive Care Med       Date:  2017-10-14       Impact factor: 17.440

Review 6.  Predictors of treatment failure and clinical stability in patients with community acquired pneumonia.

Authors:  Deirdre Morley; Antoni Torres; Catia Cillóniz; Ignacio Martin-Loeches
Journal:  Ann Transl Med       Date:  2017-11

Review 7.  Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality.

Authors:  T Welte
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-01       Impact factor: 3.267

8.  Usefulness of consecutive biomarkers measurement in the management of community-acquired pneumonia.

Authors:  A Lacoma; N Rodríguez; C Prat; J Ruiz-Manzano; F Andreo; A Ramírez; A Bas; M Pérez; V Ausina; J Domínguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-08-26       Impact factor: 3.267

Review 9.  Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia.

Authors:  Mirjam Christ-Crain; Steven M Opal
Journal:  Crit Care       Date:  2010-02-08       Impact factor: 9.097

Review 10.  The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy.

Authors:  Jean-Paul Mira; Adeline Max; Pierre-Regis Burgel
Journal:  Crit Care       Date:  2008-11-26       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.